ChronicleBio opens a sign-up link on 11 August for mobile blood draws at patients’ homes. The first 250 people pay nothing. After that the test costs $400, charged at cost. “The whole point for us is not to make money,” co-founder Fidji Simo told Fortune, which first reported the plan. “It’s to collect data so we can find cures.”
Participants get a research-grade report back, plus repeat tests over time. The trucks also reach people who cannot get to a clinic at all. Many patients with severe chronic illness are bedridden, which is precisely why they rarely show up in medical datasets.
The company launched in August 2025 with Simo, chief executive Rohit Gupta and executive chairman Rishi Reddy. It has raised $15 million and moved its lab to Menlo Park, California a few weeks ago. Gupta previously ran biobanking centres at Stanford and UCSF. ChronicleBio targets POTS, ME/CFS and long COVID, conditions that affect around 300 million people worldwide on its own count.
The missing internet of biology
Simo’s framing is blunt. “If you look at LLMs, they work so well because the internet existed,” she said. “We are missing the internet of biology.” Electronic health records, she argues, are noisy and describe paperwork rather than biology.
